Cargando…

Testosterone as a Biomarker of Adverse Clinical Outcomes in SARS-CoV-2 Pneumonia

Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may affect testicles. Lower testosterone levels have been associated with worse clinical outcomes and higher mortality. Our objective was to evaluate the hypothalamic–pituitary–gonadal axis of men admitted with SARS-CoV-2 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Marinelli, Lorenzo, Beccuti, Guglielmo, Zavattaro, Marco, Cagnina, Serena, Gesmundo, Iacopo, Bona, Chiara, Lopez, Chiara, Scabini, Silvia, Canta, Francesca, Mornese Pinna, Simone, Lupia, Tommaso, Di Bisceglie, Cataldo, Ponzetto, Federico, Settanni, Fabio, De Rosa, Francesco Giuseppe, Ghigo, Ezio, Motta, Giovanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025790/
https://www.ncbi.nlm.nih.gov/pubmed/35453570
http://dx.doi.org/10.3390/biomedicines10040820
_version_ 1784690961261002752
author Marinelli, Lorenzo
Beccuti, Guglielmo
Zavattaro, Marco
Cagnina, Serena
Gesmundo, Iacopo
Bona, Chiara
Lopez, Chiara
Scabini, Silvia
Canta, Francesca
Mornese Pinna, Simone
Lupia, Tommaso
Di Bisceglie, Cataldo
Ponzetto, Federico
Settanni, Fabio
De Rosa, Francesco Giuseppe
Ghigo, Ezio
Motta, Giovanna
author_facet Marinelli, Lorenzo
Beccuti, Guglielmo
Zavattaro, Marco
Cagnina, Serena
Gesmundo, Iacopo
Bona, Chiara
Lopez, Chiara
Scabini, Silvia
Canta, Francesca
Mornese Pinna, Simone
Lupia, Tommaso
Di Bisceglie, Cataldo
Ponzetto, Federico
Settanni, Fabio
De Rosa, Francesco Giuseppe
Ghigo, Ezio
Motta, Giovanna
author_sort Marinelli, Lorenzo
collection PubMed
description Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may affect testicles. Lower testosterone levels have been associated with worse clinical outcomes and higher mortality. Our objective was to evaluate the hypothalamic–pituitary–gonadal axis of men admitted with SARS-CoV-2 pneumonia and its link with the pneumonia-treatment intensification. Short-term changes in hormonal parameters were also assessed. Methods: Men admitted with SARS-CoV-2 pneumonia were recruited in two different hospitals in Piedmont, Italy. In all patients, the assessment of total testosterone (TT), calculated free testosterone (cFT), gonadotropins, inhibin B (InhB), and other biochemical evaluations were performed at admission (T0) and before discharge (T1). Through a review of medical records, clinical history was recorded, including data on pneumonia severity. Results: Thirty-five men (median age 64 [58–74] years) were recruited. Lower TT and cFT levels at T0 were associated with CPAP therapy (p = 0.045 and 0.028, respectively), even after adjusting for age and PaO(2)/FIO(2) ratio in a multivariable analysis. In those discharged alive, lower TT and cFT levels were associated with longer hospital stay (p < 0.01). TT, cFT, and InhB were below the normal range at T0 and significantly increased at T1 (TT 1.98 [1.30–2.72] vs. 2.53 [1.28–3.37] ng/mL, p = 0.038; cFT (0.0441 [0.0256–0.0742] vs. 0.0702 [0.0314–0.0778] ng/mL, p = 0.046; InhB 60.75 [25.35–88.02] vs. 77.05 [51.15–134.50], p < 0.01). Conclusions: Both TT and cFT levels are associated with adverse clinical outcomes in men admitted with SARS-CoV-2 pneumonia. As TT, cFT and InhB levels increase before discharge, short-term functional recovery of steroidogenesis and an indirect improvement of spermatozoa functional status could be hypothesized.
format Online
Article
Text
id pubmed-9025790
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90257902022-04-23 Testosterone as a Biomarker of Adverse Clinical Outcomes in SARS-CoV-2 Pneumonia Marinelli, Lorenzo Beccuti, Guglielmo Zavattaro, Marco Cagnina, Serena Gesmundo, Iacopo Bona, Chiara Lopez, Chiara Scabini, Silvia Canta, Francesca Mornese Pinna, Simone Lupia, Tommaso Di Bisceglie, Cataldo Ponzetto, Federico Settanni, Fabio De Rosa, Francesco Giuseppe Ghigo, Ezio Motta, Giovanna Biomedicines Article Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may affect testicles. Lower testosterone levels have been associated with worse clinical outcomes and higher mortality. Our objective was to evaluate the hypothalamic–pituitary–gonadal axis of men admitted with SARS-CoV-2 pneumonia and its link with the pneumonia-treatment intensification. Short-term changes in hormonal parameters were also assessed. Methods: Men admitted with SARS-CoV-2 pneumonia were recruited in two different hospitals in Piedmont, Italy. In all patients, the assessment of total testosterone (TT), calculated free testosterone (cFT), gonadotropins, inhibin B (InhB), and other biochemical evaluations were performed at admission (T0) and before discharge (T1). Through a review of medical records, clinical history was recorded, including data on pneumonia severity. Results: Thirty-five men (median age 64 [58–74] years) were recruited. Lower TT and cFT levels at T0 were associated with CPAP therapy (p = 0.045 and 0.028, respectively), even after adjusting for age and PaO(2)/FIO(2) ratio in a multivariable analysis. In those discharged alive, lower TT and cFT levels were associated with longer hospital stay (p < 0.01). TT, cFT, and InhB were below the normal range at T0 and significantly increased at T1 (TT 1.98 [1.30–2.72] vs. 2.53 [1.28–3.37] ng/mL, p = 0.038; cFT (0.0441 [0.0256–0.0742] vs. 0.0702 [0.0314–0.0778] ng/mL, p = 0.046; InhB 60.75 [25.35–88.02] vs. 77.05 [51.15–134.50], p < 0.01). Conclusions: Both TT and cFT levels are associated with adverse clinical outcomes in men admitted with SARS-CoV-2 pneumonia. As TT, cFT and InhB levels increase before discharge, short-term functional recovery of steroidogenesis and an indirect improvement of spermatozoa functional status could be hypothesized. MDPI 2022-03-31 /pmc/articles/PMC9025790/ /pubmed/35453570 http://dx.doi.org/10.3390/biomedicines10040820 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Marinelli, Lorenzo
Beccuti, Guglielmo
Zavattaro, Marco
Cagnina, Serena
Gesmundo, Iacopo
Bona, Chiara
Lopez, Chiara
Scabini, Silvia
Canta, Francesca
Mornese Pinna, Simone
Lupia, Tommaso
Di Bisceglie, Cataldo
Ponzetto, Federico
Settanni, Fabio
De Rosa, Francesco Giuseppe
Ghigo, Ezio
Motta, Giovanna
Testosterone as a Biomarker of Adverse Clinical Outcomes in SARS-CoV-2 Pneumonia
title Testosterone as a Biomarker of Adverse Clinical Outcomes in SARS-CoV-2 Pneumonia
title_full Testosterone as a Biomarker of Adverse Clinical Outcomes in SARS-CoV-2 Pneumonia
title_fullStr Testosterone as a Biomarker of Adverse Clinical Outcomes in SARS-CoV-2 Pneumonia
title_full_unstemmed Testosterone as a Biomarker of Adverse Clinical Outcomes in SARS-CoV-2 Pneumonia
title_short Testosterone as a Biomarker of Adverse Clinical Outcomes in SARS-CoV-2 Pneumonia
title_sort testosterone as a biomarker of adverse clinical outcomes in sars-cov-2 pneumonia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025790/
https://www.ncbi.nlm.nih.gov/pubmed/35453570
http://dx.doi.org/10.3390/biomedicines10040820
work_keys_str_mv AT marinellilorenzo testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia
AT beccutiguglielmo testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia
AT zavattaromarco testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia
AT cagninaserena testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia
AT gesmundoiacopo testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia
AT bonachiara testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia
AT lopezchiara testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia
AT scabinisilvia testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia
AT cantafrancesca testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia
AT mornesepinnasimone testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia
AT lupiatommaso testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia
AT dibiscegliecataldo testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia
AT ponzettofederico testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia
AT settannifabio testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia
AT derosafrancescogiuseppe testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia
AT ghigoezio testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia
AT mottagiovanna testosteroneasabiomarkerofadverseclinicaloutcomesinsarscov2pneumonia